UniSuper Management Pty Ltd Increases Stock Position in Pfizer Inc. $PFE

Key Points

• UniSuper Management Pty Ltd increased its stake in Pfizer Inc. by 3.6%, owning 362,283 shares valued at $9.18 million.
• Pfizer's recent earnings report showed an EPS of $0.78, exceeding expectations, with revenue of $14.65 billion for the quarter—a 10.3% increase year-over-year.
• The company announced a quarterly dividend of $0.43 per share, resulting in an annualized dividend yield of 6.9%.

UniSuper Management Pty Ltd lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 3.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 362,283 shares of the biopharmaceutical company's stock after purchasing an additional 12,538 shares during the period. UniSuper Management Pty Ltd's holdings in Pfizer were worth $9,180,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. Triumph Capital Management lifted its stake in Pfizer by 20.0% in the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock worth $273,000 after acquiring an additional 1,717 shares during the period. Centiva Capital LP boosted its holdings in Pfizer by 75.2% in the fourth quarter. Centiva Capital LP now owns 16,875 shares of the biopharmaceutical company's stock valued at $448,000 after acquiring an additional 7,244 shares in the last quarter. Finally, Focus Partners Wealth increased its position in Pfizer by 65.6% during the 4th quarter. Focus Partners Wealth now owns 1,311,901 shares of the biopharmaceutical company's stock valued at $35,077,000 after purchasing an additional 519,522 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on PFE. Jefferies Financial Group raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Finally, Bank of America upped their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Pfizer has an average rating of "Hold" and an average target price of $28.12.

Pfizer Stock Up 1.1%

Shares of PFE traded up $0.27 during mid-day trading on Thursday, reaching $24.84. The company had a trading volume of 36,770,116 shares, compared to its average volume of 34,782,688. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $141.23 billion, a price-to-earnings ratio of 13.21, a price-to-earnings-growth ratio of 0.87 and a beta of 0.55. The firm has a 50-day moving average price of $24.82 and a 200 day moving average price of $24.32. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the business earned $0.60 earnings per share. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer's payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.